Decreased serum levels of glycerol-3- phosphate dehydrogenase 1 and monoacylglycerol lipase act as diagnostic biomarkers for breast cancer

2021 ◽  
pp. 1-10
Author(s):  
Kubra Karaosmanoglu Yoneten ◽  
Murat Kasap ◽  
Kazim Yalcin Arga ◽  
Gurler Akpinar ◽  
Nihat Zafer Utkan
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Serum Levels ◽  
Monoacylglycerol Lipase ◽  
Diagnostic Biomarker ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Incidence And Mortality ◽  
Glycerol 3 Phosphate Dehydrogenase ◽  
Early Diagnostic

BACKGROUND: Breast cancer (BC) is one of the most life-threatening cancer types among women. Despite major developments in medical sciences and technologies, the incidence and mortality rates of BC cases are still increasing. One of the reasons for this increase is the absence of an easy to perform early-diagnostic tool. Although there are defined BC biomarkers routinely used for diagnostic and prognostic purposes, none of these biomarkers is useful for early diagnosis. Therefore, early diagnosis of BC remains an important challenge and there is a great need for the early-diagnostic biomarker(s). OBJECTIVE: In this study, we aimed to evaluate the diagnostic and prognostic values of glycerol-3-phosphate dehydrogenase (GPD1) and monoacylglycerol lipase (MAGL) proteins as non-invasive serum biomarkers. METHODS: GPD1 and MAGL serum levels were determined by ELISA for BC patients (n= 100) from five different subtypes, and healthy controls (n= 20), and a comparative analysis was performed to determine statistically significant expression differences among the groups. RESULTS: The results provided evidence that GPD1 acted as a diagnostic biomarker in distinguishing triple-negative breast cancer (TNBC) patients from other subtypes, and MAGL acted as a diagnostic biomarker in distinguishing healthy individuals from BC patients. CONCLUSION: GPD1 and MAGL might be proposed as non-invasive diagnostic biomarkers for BC with high sensitivity and specificity.

scholarly journals Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2848
Author(s):  
Anna Adam-Artigues ◽  
Iris Garrido-Cano ◽  
Juan Antonio Carbonell-Asins ◽  
Ana Lameirinhas ◽  
Soraya Simón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Principal Component ◽  
Enrichment Analysis ◽  
Pathway Enrichment Analysis ◽  
Roc Curve Analysis ◽  
Diagnostic Biomarkers ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Parameter Evaluation

The early diagnosis of breast cancer is essential to improve patients’ survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs.

MicroRNAs: New non-invasive diagnostic biomarkers and therapeutic method for cancer treatment

2021 ◽  
Vol 3 (1) ◽  
pp. 1-12
Author(s):  
Tamadir Aledani ◽  
Kassim Abdulkareem
Keyword(s):  
Early Diagnosis ◽  
Low Cost ◽  
Diagnosis And Treatment ◽  
Messenger Rnas ◽  
Multiple Cancer ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Cancer Types ◽  
Tumor Suppressive Mirnas ◽  
Exciting Possibility

Background: Cancer is a global health problem and the main cause of mortality. Most cancerassociated cases of mortality are the consequences of lack of effective treatment and biomarkers for early diagnosis. New hopes for the improvement of the early diagnosis and treatment of cancer synchronize with the emergence of microRNAs (miRNAs). MicroRNAs are small, noncoding, single-stranded RNAs, the length of which is approximately 18–25 nucleotides and which bind to 3’ untranslated region (3’UTR) of the target messenger RNAs (mRNAs), leading to mRNA degradation or translational inhibition; thereby regulating gene expression posttranscriptionally. Aim: Using microRNAs as promising and potential biomarkers for diagnosis and therapeutic targets. Methods: The microRNA expression changes in peripheral blood and can be assayed using non-invasive, low-cost, precise, and rapid tools. Results: It is noteworthy that miRNAs participate in multiple cancer-related biological processes, including proliferation, apoptosis, angiogenesis, drug resistance, invasion, and metastasis. Interestingly, the identified cancer-associated miRNAs, including over-expressed oncogenic miRNAs (oncomiRs) or underexpressed tumor-suppressive miRNAs, are diverse and specific for different tissues and cancer types. Conclusion: The genetic testing of microRNAs opens up the exciting possibility of early diagnosis and treatment before the onset of metastasis. Keywords: microRNAs, gene silencing, circulating biomarkers, cancer diagnosis, anticancer therapy, miRNAs detection.

scholarly journals Non-Invasive Biomarkers for Early Detection of Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2767
Author(s):  
Jiawei Li ◽  
Xin Guan ◽  
Zhimin Fan ◽  
Lai-Ming Ching ◽  
Yan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
False Negative ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Biomarkers ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Common Cancer ◽  
Volatile Organic

Breast cancer is the most common cancer in women worldwide. Accurate early diagnosis of breast cancer is critical in the management of the disease. Although mammogram screening has been widely used for breast cancer screening, high false-positive and false-negative rates and radiation from mammography have always been a concern. Over the last 20 years, the emergence of “omics” strategies has resulted in significant advances in the search for non-invasive biomarkers for breast cancer diagnosis at an early stage. Circulating carcinoma antigens, circulating tumor cells, circulating cell-free tumor nucleic acids (DNA or RNA), circulating microRNAs, and circulating extracellular vesicles in the peripheral blood, nipple aspirate fluid, sweat, urine, and tears, as well as volatile organic compounds in the breath, have emerged as potential non-invasive diagnostic biomarkers to supplement current clinical approaches to earlier detection of breast cancer. In this review, we summarize the current progress of research in these areas.

scholarly journals Development of a hoRizontal data intEgration classifier for NOn-invasive early diAgnosis of breasT cancEr: the RENOVATE study protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e054256
Author(s):  
Francesco Ravera ◽  
Gabriella Cirmena ◽  
Martina Dameri ◽  
Maurizio Gallo ◽  
Valerio Gaetano Vellone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Data Integration ◽  
Breast Biopsy ◽  
Translational Study ◽  
Non Invasive ◽  
Standard Procedures ◽  
Patient Will ◽  
Diagnostic Biopsy ◽  
Registration Number

IntroductionStandard procedures aimed at the early diagnosis of breast cancer (BC) present suboptimal accuracy and imply the execution of invasive and sometimes unnecessary tissue biopsies. The assessment of circulating biomarkers for diagnostic purposes, together with radiomics, is of great potential in BC management.Methods and analysisThis is a prospective translational study investigating the accuracy of the combined assessment of multiple circulating analytes together with radiomic variables for early BC diagnosis. Up to 750 patients will be recruited at their presentation at the Diagnostic Senology Unit of Ospedale Policlinico San Martino (Genoa, IT) for the execution of a diagnostic biopsy after the detection of a suspect breast lesion (t0). Each recruited patient will be asked to donate peripheral blood and urine before undergoing breast biopsy. Blood and urine samples will also be collected from a cohort of 100 patients with negative mammography. For cases with histological diagnosis of invasive BC, a second sample of blood and urine will be collected after breast surgery. Circulating tumour DNA, cell-free methylated DNA and circulating proteins will be assessed in samples collected at t0 from patients with stage I–IIA BC at surgery together with those collected from patients with histologically confirmed benign lesions of similar size and from healthy controls with negative mammography. These analyses will be combined with radiomic variables extracted with freeware algorithms applied to cases and matched controls for which digital mammography is available. The overall goal of the present study is to develop a horizontal data integration classifier for the early diagnosis of BC.Ethics and disseminationThis research protocol has been approved by Regione Liguria Ethics Committee (reference number: 2019/75, study ID: 4452). Patients will be required to provide written informed consent. Results will be published in international peer-reviewed scientific journals.Trial registration numberNCT04781062.

scholarly journals A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer

2021 ◽  
Vol 22 (11) ◽  
pp. 6121
Author(s):  
Maha M. Itani ◽  
Farah J. Nassar ◽  
Arafat H. Tfayli ◽  
Rabih S. Talhouk ◽  
Ghada K. Chamandi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Healthy Controls ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Predominant Type ◽  
New Biomarkers ◽  
Microrna Microarray

Breast cancer (BC) is the most predominant type of cancer among women. The aim of this study is to find new biomarkers that can help in early detection of BC, especially for those who are too young to be screened using mammography as per guidelines. Using microRNA microarray, we previously showed dysregulation of 74 microRNAs in tumors from early BC patients as compared with normal adjacent tissues, which we were interested in studying in blood circulation. In this study, we investigated the expression of 12 microRNA (miR-21/miR-155/miR-23a/miR-130a/miR-145/miR-425-5p/miR-139-5p/miR-451/miR-195/miR-125b/miR-100, and miR-182) in the plasma of 41 newly diagnosed Lebanese BC patients with early invasive ductal carcinoma as compared with 32 healthy controls. Total RNA was extracted from plasma, and expression levels of miRNA of interest were measured using RT-qPCR followed by statistical analysis; miR-21, miR-155, miR-23a, miR-130a, miR-145, miR-425-5p, and miR-139-5p were significantly upregulated and miR-451 was significantly downregulated, in the plasma of BC patients as compared with healthy controls. The positively correlated miR-23a, miR-21, and miR-130a had a high diagnostic accuracy (86%). Importantly, the combination of miR-145/miR-425-5p/miR-139-5p/miR-130a scored the highest diagnostic accuracy of 95% with AUC = 0.97 (sensitivity 97% and specificity 91%). MicroRNAs are promising non-invasive diagnostic biomarkers for early-stage BC with the panel of miR-145/miR-425-5p/miR-139-5p/miR-130a having the highest diagnostic accuracy.

scholarly journals Evaluation of Plasma MMP-9 and VEGF-A mRNAs as Non-invasive Diagnostic Biomarkers in Women with Endometriosis

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Sepideh Abdollahi ◽  
Pantea Izadi ◽  
Shahla Noori Ardebili ◽  
Samaneh Chegeni ◽  
Mir Saead Yekaninejad
Keyword(s):  
Plasma Level ◽  
Quantitative Polymerase Chain Reaction ◽  
Mrna Level ◽  
Control Group ◽  
P Value ◽  
Mrna Levels ◽  
Diagnostic Biomarker ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Significant Difference

Background: Endometriosis is one of the common gynecological diseases and can lead to pelvic pain, dysmenorrhea, dyspareunia, and infertility in women. Thus, accurate and early diagnosis is a pivotal issue and an essential need for managing this disorder. At the present, the gold standard diagnostic method for endometriosis is laparoscopic surgery that is an invasive method and can lead to delay in diagnosis. Thus, there is an immediate necessity to search for non-invasive diagnostic biomarkers, such as blood-based ones. Objectives: Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor-A (VEGF-A) have essential roles in the pathogenesis of endometriosis. Therefore, in this study, we evaluated the plasma mRNA levels of MMP-9 and VEGF-A, as potential non-invasive diagnostic biomarkers for endometriosis. Methods: This study included 48 women (24 cases and 24 controls) who underwent laparoscopy for suspected endometriosis. Preoperative plasma samples were collected, and after RNA extraction, the levels of MMP-9 and VEGF-A mRNAs were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Results: Plasma MMP-9 mRNA level was statistically higher in endometriosis patients compared with the control group (P value = 0.01). However, plasma VEGF-A mRNA level did not show a significant difference between the two groups (P value =0.5). Conclusions: It seems that the plasma level of MMP-9 mRNA in endometriosis patients is significantly higher than in non-endometriosis women. This finding can provide new insights regarding this mRNA’s applicability as a non-invasive diagnostic biomarker for discovering new cases of endometriosis (newly diagnosed). According to our results, despite the suggested role of VEGF-A in endometriosis pathogenesis, it seems that the plasma level of VEGF-A mRNA does not have the potential to be used as a non-invasive diagnostic biomarker.

Sign in / Sign up

Export Citation Format

Share Document